Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984757 | 0.88 | SIGMAR1 (0.63) | SIGMAR1POLBHRH3HTTKMT2A | |
| SCHEMBL14320637 | 0.85 | L3MBTL3 (0.64) | SIGMAR1L3MBTL3HRH3MBTD1L3MBTL1 | |
| SCHEMBL5651768 | 0.82 | SIGMAR1 (0.64) | SIGMAR1L3MBTL3HRH3MBTD1L3MBTL1 | |
| SCHEMBL1877934 | 0.82 | HRH3 (0.68) | SIGMAR1L3MBTL3HRH3MBTD1L3MBTL1 | |
| SCHEMBL15137345 | 0.82 | SIGMAR1 (0.57) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL23146342 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL25042302 | 0.81 | SIGMAR1 (0.65) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL24351544 | 0.81 | SIGMAR1 (0.70) | SIGMAR1POLBL3MBTL3CD274HRH3 | |
| SCHEMBL22711455 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL24022514 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | claimed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | claimed |
| WO-2007092879-A2 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | WO | claimed |
| CN-116120300-B | Pyrimidine compound containing hydroxamic acid fragment, and preparation method and application thereof | 贵州大学 | 2024-10-15 | — | — | CN | disclosed |
| US-11851436-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023237759-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR | ANAGENESIS BIOTECHNOLOGIES (FR) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |
| CN-114181199-B | 2, 4-disubstituted pyrimidine derivative, preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116120300-A | Pyrimidine compound containing hydroxamic acid fragment, and preparation method and application thereof | 贵州大学 | 2023-05-16 | — | — | CN | disclosed |
| US-20230029430-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2023-01-26 | — | — | US | disclosed |
| CN-114181199-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-1115704-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-07-18 | — | — | EP | disclosed |
| CN-1303374-A | Substituted indolinones, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-07-11 | — | — | CN | disclosed |
| EP-1100779-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| EP-1071665-A1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| US-6169106-B1 | ANTITUMOUR AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-01-02 | — | — | US | disclosed |
| WO-2000018734-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999062882-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999052869-A1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | SIGMAR1 4454/4885POLB 4243/4885L3MBTL3 2136/4885 |
| US-11851436-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DPYD, TYMP, NUDT21 | SIGMAR1 2316/4885POLB 631/4885L3MBTL3 3833/4885 |
| US-20230029430-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DPYD, TYMP, NUDT21 | SIGMAR1 2316/4885POLB 631/4885L3MBTL3 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.